Targeting N-Terminal Pyroglutamate Modification in Alzheimer's & Inflammation
As the enzymatic driver of pyroglutamate formation at N-terminal glutamine residues, QPCT (Glutaminyl-peptide cyclotransferase, QC) represents a critical intervention point for Alzheimer's disease (AD) pathogenesis and inflammatory disorders. The conversion of truncated amyloid-beta (Aβ) to pyroglutamate-Aβ (pGlu-Aβ) by QPCT significantly enhances aggregation propensity and neurotoxicity, positioning QPCT inhibitors as disease-modifying candidates. Beyond AD, QPCT is also implicated in chronic inflammation and, through its paralog QPCTL, in the CD47/SIRPα immune checkpoint axis relevant to oncology. TarMart provides the high-fidelity enzymatic reagents and ortholog-specific tools required to advance selective QPCT inhibitor programs.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for QPCT drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | QPCT Recombinant Protein High purity (>95%), Sequence Verified, Enzymatic Activity Compatible, Endotoxin <1 EU/µg. HEK293 or E.coli expression available. |
View QPCT Products |
| Gene Delivery | QPCT ORF cDNA / Lentivirus Full-length coding sequence for stable cell line generation. CMV promoter, Puromycin selection. |
View QPCT Products |
| Validation Standard | Anti-QPCT Monoclonal Antibody Sequence-defined positive control for Western/IP applications. |
View QPCT Products |
| Functional Validator | QPCT siRNA Set (3 unique targets) For enzymatic knockdown validation and specificity controls. |
View QPCT Products |
| Selectivity Counter-screen | QPCTL (Paralog) Recombinant Protein Critical for specificity assays; shares ~50% homology with QPCT. High purity (>95%). |
View QPCTL Products |
| Pathway Context 1 | ADAMTS4 Recombinant Protein Related to Aβ processing cascade; complementary target for combination therapy screening. |
View ADAMTS4 Products |
| Pathway Context 2 | APP Recombinant Protein Substrate pathway for Alzheimer's disease modeling; supports full Aβ modification cascade assays. |
View APP Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Selectivity (QPCT vs QPCTL) | Matched pair of Human QPCT and QPCTL proteins (>95% purity) for orthogonal counter-screening; sequence verified by mass spec. |
| Cross-species Translation (Alzheimer's Models) | Human, Mouse, and Cynomolgus Monkey QPCT orthologs available with identical purity standards; enable seamless preclinical transition. |
| Enzymatic Activity Standardization | Active enzyme format suitable for fluorogenic substrate assays (H-Gln-AMC based); high batch-to-batch consistency with endotoxin <1 EU/µg. |
| False Positive Elimination & Controls | Validated QPCT siRNA and neutralizing antibody controls included for target engagement verification; clinical benchmark antibodies also available for assay standardization. |
Global Clinical Landscape & Future Outlook
The QPCT inhibitor landscape is transitioning from early-phase Alzheimer's trials toward refined selectivity profiles. First-generation small molecules (e.g., PQ912 by Probiodrug/Sygnis, Varoglutamstat by Vivoryon Therapeutics) demonstrated target engagement but highlighted the critical necessity of discriminating between QPCT and its paralog QPCTL to avoid off-target immune modulation. As the field advances, the next wave of R&D focuses on blood-brain barrier (BBB) penetrant compounds with exquisite selectivity profiles and combination approaches with BACE inhibitors, ADAMTS modulators, or anti-pGlu-Aβ antibodies (e.g., Donanemab). Concurrently, interest in QPCTL for oncology – particularly in CD47/SIRPα checkpoint signaling – is driving exploration of dual QPCT/QPCTL inhibitors or selective QPCTL modulators, expanding the therapeutic landscape beyond neurodegeneration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Selective QPCT) | Probiodrug/Sygnis, Vivoryon Therapeutics | Alzheimer's Disease, Inflammation | Enzymatic Activity & Selectivity vs QPCTL (Need matched protein pair) |
| Small Molecule / Dual Inhibitor (QPCT/QPCTL) | Preclinical Biotech | Oncology, Neurodegeneration | Selectivity Assay (Need QPCT & QPCTL recombinant proteins + counter-screen) |
| Allosteric Modulator | Early Discovery | Neurodegeneration | Conformational Assays (Need full-length native protein) |
| Biological (siRNA/mRNA) | Preclinical | Peripheral Inflammation | Cell-based KD validation (Need lentivirus/siRNA tools) |
| Antibody (Anti-pGlu-Aβ) | Eli Lilly (Donanemab pathway context) | Alzheimer's Disease | Substrate validation (Need consistent enzymatic modification assays + APP protein) |
Live QPCT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: